BHV-1300 Begins Phase 3: Biohaven’s Precision Immunology Approach Takes Aim at Root Cause of Graves’ Disease
Market Chameleon (Mon, 29-Jun 8:36 AM)
Biohaven’s Opakalim Data Shows 3-Fold Reduction in Seizure Events and Low Side Effects in Epilepsy Trials
Market Chameleon (Tue, 26-May 9:24 AM)
